Corvus Pharmaceuticals, Inc(NASDAQ:CRVS) 
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of aden...
Website: http://www.corvuspharma.com
Founded: 2014
Full Time Employees: 52
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 2.90
H 2.96
L 2.71
C 2.85
V 832,026
10EMA 2.85
20EMA 2.85
60EMA 2.85
120EMA 2.85
250EMA 2.85